Join Now

Author Archives: Natalie Themm

PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board

PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board

Posted in BioUtah News | Tagged | Comments Off on PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board

Owlet Unveils ‘Owlet360’ – Turning Infant Health Data Into Peace of Mind for Parents

This new subscription service, exclusive to Owlet users, gives parents a deeper, personalized understanding of their baby’s development, health, and sleep trends.

Posted in BioUtah News | Tagged | Comments Off on Owlet Unveils ‘Owlet360’ – Turning Infant Health Data Into Peace of Mind for Parents

Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Opening plenary session features latest fetal fraction amplification research

Posted in BioUtah News | Tagged | Comments Off on Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference

Life Sciences Day on the Hill 2025

The Capitol Rotunda was filled with exhibits from over 25 local life sciences companies.

Posted in BioUtah News, Life Sciences Events | Tagged | Comments Off on Life Sciences Day on the Hill 2025

Ultradent Donating to Southern California Fire Relief

Ultradent Donating to Southern California Fire Relief

Posted in BioUtah News | Tagged | Comments Off on Ultradent Donating to Southern California Fire Relief

Canyon Labs Announces Strategic Acquisition of iuvo BioScience’s Lab Services and Consulting Businesses to Expand End-to-End Development Solutions

Transaction positions iuvo BioScience for continued growth as an industry leader in ophthalmic clinical research

Posted in BioUtah News | Tagged | Comments Off on Canyon Labs Announces Strategic Acquisition of iuvo BioScience’s Lab Services and Consulting Businesses to Expand End-to-End Development Solutions

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway

Posted in BioUtah News | Tagged | Comments Off on Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Posted in BioUtah News | Tagged | Comments Off on Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Posted in BioUtah News | Tagged | Comments Off on MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs

Posted in BioUtah News | Tagged | Comments Off on M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

Sethera Therapeutics Completes First Funding Round

Sethera Therapeutics Completes First Funding Round

Posted in BioUtah News | Tagged | Comments Off on Sethera Therapeutics Completes First Funding Round

Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

Data from Dual-Acting Oral Biologic Show Promising Safety and Efficacy Profile

Posted in BioUtah News | Tagged | Comments Off on Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis